Introduction {#s1}
============

As antiretroviral therapy (ART) has been scaled up in sub-Saharan Africa, attention has focused on the problem of high rates of mortality in the first months of ART. [@pone.0047542-Bisson1], [@pone.0047542-Lawn1] Even when controlling for the state of immunodeficiency and opportunistic infections, patients in low-income settings have been shown to have significantly higher rates of early mortality compared to patients in high-income settings. [@pone.0047542-Braitstein1] The reasons for this excess of early mortality are poorly understood.[@pone.0047542-Nojilana1]--[@pone.0047542-Wester1] To date studies addressing the etiology of these deaths have utilized chart-review and verbal autopsy, both of which are highly discordant with the gold standard of pathological autopsy.[@pone.0047542-Castelnuovo1]--[@pone.0047542-Cox1] Few pathological studies of adult patients dying of HIV-related illnesses in developing countries have been done, and none of these have included patients being treated with ART.[@pone.0047542-Martinson1]--[@pone.0047542-Greenberg1].

To better understand causes of death in this group, we conducted a prospective post-mortem study of adults on ART who died after being admitted to hospital in Johannesburg, South Africa. A control group consisted of patients with advanced AIDS who were eligible for ART but had not yet received it. We ascertained causes of death though needle autopsy, chart review, and consideration of each case at a standardized clinico-pathologic conference.

Methods {#s2}
=======

Ethics Statement {#s2a}
----------------

The study was approved by the Ethics Committee of the University of Witwatersrand and the Institutional Review Board of Vanderbilt University. Subjects were consented into the study by one of two methods. Competent and willing subjects provided written consent for enrollment in the event of their death. After the death of disoriented or unconscious subjects, the next of kin provided written consent for participation. All clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki.

Setting and Subject Eligibility {#s2b}
-------------------------------

Data were prospectively collected at Charlotte Makexe Johannesburg Academic Hospital, a 1088-bed, public, tertiary hospital located in central Johannesburg with a free ART program of over 3000 patients. At the time of the study, South African national guidelines allowed for ART initiation in patients with CD4 cell count [\<]{.ul}200 cells/mm^3^. In 2009, the HIV prevalence rate for Johannesburg's province was 11.3% of the adult population; the reporting rate for tuberculosis cases was 469.9 per 100,000 per annum. [@pone.0047542-Accessed1].

Eligibility criteria for this study were: age [\>]{.ul}18 years, HIV-positive, either on ART or eligible for ART, and death occurring on one of the medical wards. Exclusion criteria were pregnancy and a history of defaulting or restarting ART.

Study Procedures {#s2c}
----------------

### Record review of pre-mortem data {#s2c1}

A chart review was undertaken for each enrolled subject. Variables collected included: history of HIV and ART, history of tuberculosis (TB) and treatment, other comorbidities and opportunistic infections, clinical features of the presenting illness, and all radiology and laboratory results from hospital admission until the time of death.

### Needle autopsy {#s2c2}

The needle autopsy method was chosen because it can identify a pathogen in a significant proportion of HIV deaths and is faster, cheaper, and more acceptable to families than conventional autopsy. [@pone.0047542-Baumgart1]--[@pone.0047542-Satyanarayana1] As soon as possible after death, investigators aspirated cerebrospinal fluid (CSF) and performed standardized needle biopsies of the lungs (focusing on areas of abnormality on pre-mortem chest x-ray), liver, spleen, kidneys, and bone marrow. Additional biopsies of the heart, skin, lymph nodes and any accessible masses were obtained when pre- or post-mortem abnormalities were present. An ultrasound was used to locate the kidneys, spleen and heart. Other organs were located by external anatomical landmarks. Half-centimeter incisions were made in the skin overlying each biopsy site and closed with single sutures to achieve minimal cosmetic disturbance. Solid organ biopsies were obtained with 14-gauge core biopsy needles, bone marrow trephines with 14-gauge Jamshidi needles, CSF aspirated with 18-gauge syringes, and skin biopsied with standard punch tools. Multiple core biopsies (2 to 4 per skin incision) were obtained from the solid organs (lung, liver, spleen and kidney); biopsy specimens were, on average, 1.6 mm in diameter and ranged from 4--20 mm in length. Needle autopsies were performed by two investigators (E.B.W. and G.J.S.).

### Histologic investigations {#s2c3}

Tissue cores from each organ were preserved in formalin, embedded in paraffin and stained with Hematoxylin-eosin, Ziehl-Neelsen (ZN) for acid fast organisms, and Brown-Hopps modified tissue gram stain. Lung cores were stained with Grocott's Methanamine Silver for fungi. Cytomegalovirus immunoperoxidase staining was performed when characteristic viral inclusions were noted. Additional immunohistochemical and special stains were performed as needed. Cytological examination was performed on CSF. Tissue processing and stains were performed by the National Health Laboratory Service with all interpretation performed by the study pathologist (T.O.).

### Microbiologic investigations {#s2c4}

Tissue cores were obtained using sterile technique and transported for same day processing. Specimens were subjected to aerobic and anaerobic bacterial cultures (lung, spleen); fungal culture (lung, spleen and CSF); mycobacterial culture (lung, spleen, liver, bone marrow, lymph node and CSF) and cryptococcal antigen testing (CSF). Antibiotic sensitivities were performed for positive bacterial cultures. Mycobacterial cultures were performed using the Bactec MGIT system (Becton Dickinson, New Jersey, USA) followed by species identification using the GenoType Mycobacterium CM Assay (Hain Lifesciences, Nehren, Germany) at the Johannesburg Tuberculosis Reference Laboratory. Real-time PCR-based LightCycler Mycobacterium detection assay (Roche Diagnostics, Germany) was performed on lung, liver, lymph node and CSF; specimens with sufficient leftover volume were also tested in the Xpert MTB/RIF PCR (Cepheid, California, USA) assay. Details of tissue preparation for the PCR assays have been published separately. [@pone.0047542-Gous1].

### Clinico-pathologic conferences {#s2c5}

A committee of experienced infectious disease, pulmonary and pathology specialists from South Africa and the United States (C.F., D.M., N.M., R.O., T.O., G.S., W.D.F.V., E.W.) met at three clinico-pathologic conferences to adjudicate the immediate and contributing causes of death for each subject. The immediate cause of death was defined as the disease or condition directly leading to death whereas the contributing causes of death included other diseases or conditions believed to have contributed to the fatal outcome. [@pone.0047542-Hanzlick1] The committee reviewed the clinical history, pre-mortem investigations, post-mortem microbiology and post-mortem histology of each subject. A pre-designated rule dictated the interpretation of post-mortem bacterial and fungal cultures: an organism was considered pathologic only if 1) the same organism was cultured in pre-mortem culture or if 2) the affected organ showed appropriate vital inflammation on histology.

### Categorization of causes of death {#s2c6}

Causes of death were categorized as bacterial, fungal, mycobacterial, viral (non-HIV), neoplastic and non-infectious organ failure. Immune Reconstitution Inflammatory Syndrome (IRIS) was defined as worsening of disease with signs of clinically significant inflammation within 90 days of ART initiation despite appropriate treatment. TB IRIS was further defined as either paradoxical (known TB diagnosis with initial improvement on anti-tubercular therapy and subsequent paradoxical worsening) or unmasking (diagnosis of inflammatory TB within 90 days of ART initiation in a patient previously free of TB) in accordance with published consensus definitions. [@pone.0047542-Meintjes1] Causes of death were defined as unsuspected by clinicians if they were revealed solely by the post-mortem investigations. Subjects in whom a cause of death remained imprecisely understood due to limitations of the post-mortem technique (ie. lack of sampling of the gastrointestinal tract or brain) were also recorded.

Analysis {#s2d}
--------

Baseline characteristics and the proportion of deaths attributable to each category were calculated overall and in three pre-planned sub-groups: pre-ART (\<7 days of ART at the time of death), early-ART mortality (7--90 days of ART at the time of death), and late-ART mortality (\>90 days of ART at the time of death). One-way analysis of variance and Fisher's exact test were used to determine association between baseline characteristics and categories of mortality in these three groups. The sample size was dictated by the available budget.

Results {#s3}
=======

Pre-mortem Characteristics {#s3a}
--------------------------

From January -- December 2009, 39 HIV-infected adults were enrolled. Six (15%) consented themselves prior to death; 33 (85%) were consented by family members after death. Half were women, median age was 36 years (IQR 32--40) and median CD4 count was 50 cells/mm^3^ (IQR 27--154, [Table 1](#pone-0047542-t001){ref-type="table"}). Median length of hospitalization was 5 days (IQR 2--13) and 3 subjects received intensive care. Thirteen (33%) had received a diagnosis of tuberculosis and were on anti-tuberculosis therapy at the time of admission. Fourteen (36%) were on sulfamethoxazole-trimethoprim prophylaxis at the time of admission. Thirty-five (90%) received broad-spectrum antibiotics (most commonly amoxicillin/clavulanic acid, ceftriaxone, or pipercillin/tazobactam) and 23 (59%) received steroids during hospitalization (most often initiated empirically due to concern for hypoaldrenalism, *P. jerovici* pneumonia or IRIS).

10.1371/journal.pone.0047542.t001

###### Pre-mortem characteristics of the study population.

![](pone.0047542.t001){#pone-0047542-t001-1}

                                                                        All deaths    Pre-ART deaths   Early-ART deaths   Late-ART deaths   p-value
  ------------------------------------------------------------------- -------------- ---------------- ------------------ ----------------- ---------
  Female, n (%)                                                          19 (49%)        5 (36%)           8 (53%)            6 (60%)        0.47
  Age in years, median (IQR)                                           36 (32--40)    37.5 (33--40)      33 (30--39)        36 (32--44)      0.30
  CD4 cells/mm^3a^, median (IQR)                                       50 (27--154)    49 (18--111)      61 (46--154)      43 (27--175)      0.50
  Days in hospital, median (IQR)                                        5 (2--13)       8 (2--15)         3 (2--11)         3.5 (1--9)       0.48
  Days of ART, median (IQR)                                                                              32 (16--50)      326 (148--531)   
  On TB treatment at admission, n (%)                                    13 (33%)        3 (21%)           7 (47%)            3 (30%)        0.36
  On sulfamethoxazole- trimethoprim prophylaxis at admission, n (%)      14 (36%)        6 (43%)           5 (33%)            3 (30%)        0.84
  Received broad-spectrum antibiotics during hospitalization, n (%)      35 (90%)       14 (100%)          14 (93%)           7 (70%)        0.07
  Received steroids during hospitalization, n (%)                        23 (59%)        9 (64%)           9 (60%)            5 (50%)        0.85

Categorized by duration of antiretroviral therapy (ART) at the time of death. Pre-ART deaths occurred in subjects who were HIV-positive and eligible for ART but had not yet received it (CD4 cell count \<200 cells/mm^3^) or those who had received \<7 days of ART. Early ART deaths occurred between 7--90 days of ART. Late ART deaths occurred after \>90 days of ART.

CD4 count measured most recently prior to death.

Twelve subjects were ART naïve and 2 had received \<7 days of ART at the time of death; in this pre-ART group the median CD4 cell count was 49 cells/mm^3^ (IQR 18--111). Twenty-five subjects received [\>]{.ul}7 days of ART at the time of death; 15 were categorized as early-ART mortality with median duration of ART 32 days (IQR 16--50) and median CD4 cell count 61 cells/mm^3^ (IQR 46--154) and 10 were categorized as late-ART mortality with median duration of ART 326 days (IQR 148--531) and median CD4 cell count 43 cells/mm^3^ (IQR 27--175). Reported CD4 cell counts were those measured most proximally to death. Details of the antiretroviral regimen were available for 21 subjects, all of whom were on two nucleoside reverse transcriptase-inhibitors (11 stavudine/lamivudine, 5 didanosine/lamivudine, 5 tenofovir/lamivudine) and one non-nucleoside reverse transcriptase inhibitor (19 efavirenz, 2 nevirapine).

Performance of the Needle Autopsy and Microbiologic Results {#s3b}
-----------------------------------------------------------

Median time from death to needle autopsy was 25 hours (range 5--55). The quality of each sample was assessed at histological examination and categorized as adequate (containing representative target tissue) or missed ([Table 2](#pone-0047542-t002){ref-type="table"}). Adequate samples were obtained from the majority of biopsies: kidney (100%), skin (100%), heart (100%), CSF (100%), lung (97%), liver (97%), bone marrow (92%), spleen (87%), lymph node (68%). Bacterial cultures of the lung were pathogenic in 26% and contaminated in 33% of samples; in the spleen bacterial culture was pathogenic in 18% and contaminated in 15%. Pathogenic bacteria cultured from lung and spleen were *E. coli* (isolated in 8 cultures), *Acinetobacter* sp. (3), *Enterobacter* sp. (3), *Klebsiella* sp. (3), *Clostridium* sp. (2), *Proteus* sp. (2), and *Salmonella* sp.(1). Mycobacterial cultures were positive in 24% of livers, 23% of spleen, 19% of lung, 16% of lymph node, 15% of bone marrow and 10% of CSF samples. Mycobacterial cultures were positive in 16 subjects; with the organism identified as *M. tuberculosis* in 13, *M. avium* in 1, and unable to be further speciated due to contamination in 2. *M. tuberculosis* was identified by PCR in the tissues of 5 additional subjects. Fungal cultures had low rates of positivity: 8% in CSF, 8% in spleen and 3% in lung. The pathogenic fungi cultured from CSF, spleen and lung were *C. neoformans* (isolated in 6 cultures) and *C. albicans* (1).

10.1371/journal.pone.0047542.t002

###### The yield of needle autopsy by site and investigation.

![](pone.0047542.t002){#pone-0047542-t002-2}

  Site                                                                Lung             Liver          Spleen         Kidney      Bone Marrow                    Lymph Node                                      Skin                                       Heart                          CSF
  ------------------------------------------------------------- ----------------- --------------- --------------- ------------ --------------- -------------------------------------------- -------------------------------------------- ------------------------------------------ ---------------
  Attempted samples, n (adequate for analysis, missed)             39 (38, 1)       39 (38, 1)      39 (34, 5)     39 (39, 0)    39 (36, 3)     19[a](#nt103){ref-type="table-fn"} (14, 5)   20[b](#nt104){ref-type="table-fn"} (20, 0)   3[c](#nt105){ref-type="table-fn"} (3, 0)    39 (39, 0)
  Bacterial culture, n (positive, negative, contaminated)        39 (10, 16, 13)                   39 (6, 26, 7)                                                                                                                                                                    
  Fungal culture, n (positive, negative, contaminated)           37 (1, 25, 12)                    39 (3, 33, 3)                                                                                                                                                                     37(3, 33, 1)
  Mycobacterial culture, n (positive, negative, contaminated)     36 (7, 21, 8)    38 (9, 24, 5)   39 (9, 26, 4)                39 (6, 36, 7)                 19 (3, 13, 3)                                                                                                          39 (4, 32, 3)
  Cryptococcal antigen, n (positive, negative)                                                                                                                                                                                                                                        27 (3, 24)
  Cytology, n (positive for neoplasm, negative)                                                                                                                                                                                                                                       30 (0, 30)

Lymph nodes were biopsied in patients with palpable lymphadenopathy on post-mortem exam.

Skin biopsy was performed in patients with rash on post-mortem exam.

Heart was biopsied if pre-mortem history was suggestive of cardiac cause of death.

Causes of Death: as Determined by the Clinico-pathologic Committee {#s3c}
------------------------------------------------------------------

Mycobacterial infection, confirmed microbiologically (in 21 cases) and/or histologically (in 26 cases), was the leading cause of death in the pre-ART (57%, 8/14) and on-ART groups (76%, 19/25) and contributed to the large majority of early-ART deaths (87%, 13/15, [Table 3](#pone-0047542-t003){ref-type="table"}). Of the 27 cases of mycobacterial infection, 25 cases were determined to be due to *M. tuberculosis*, 1 to *M. avium*; and 1 to a mycobacterial infection that could not be specified. All mycobacterial deaths had evidence of disseminated infection (microbiological and histologic evidence detailed in [Table 4](#pone-0047542-t004){ref-type="table"}). In those in whom mycobacterial infection caused death, it was the immediate cause of death in 56% (15/27). Of the 26 subjects with non-*M. avium* mycobacterial infection, 10 (37%) had been treated with TB therapy prior to admission the hospital; 7 (27%) were started on TB therapy during hospitalization and 9 (33%) were never initiated on TB therapy. Disseminated mycobacterial infection was revealed as a previously unsuspected cause of death at post-mortem in 9 subjects (6 in the early-ART mortality group).

10.1371/journal.pone.0047542.t003

###### Causes of death by category.

![](pone.0047542.t003){#pone-0047542-t003-3}

                                                                                       All deaths   Pre-ART deaths   Early-ART deaths   Late-ART deaths   p-value
  ----------------------------------------------------------------------------------- ------------ ---------------- ------------------ ----------------- ---------
  Causes of death by category[a](#nt107){ref-type="table-fn"}                                                                                            
  Mycobacterial, n (%)                                                                  27 (69%)       8 (57%)           13 (87%)           6 (60%)        0.16
  Bacterial, n (%)                                                                      13 (33%)       5 (36%)           6 (40%)            2 (20%)        0.45
  Fungal, n (%)                                                                         8 (21%)        3 (21%)           4 (27%)            1 (10%)        0.79
  Viral (non-HIV), n (%)                                                                 3 (8%)        2 (14%)            0 (0%)            1 (10%)        0.35
  Neoplasm, n (%)                                                                       10 (26%)       3 (21%)           3 (20%)            4 (40%)        0.58
  Organ dysfunction[b](#nt108){ref-type="table-fn"}, n (%)                              10 (26%)        1 (7%)           5 (33%)            4 (40%)        0.13
  Immune reconstitution inflammatory syndrome, n (%)                                    11 (28%)                         11 (73%)                        
  Unsuspected by clinicians at time of death[c](#nt109){ref-type="table-fn"}, n (%)     19 (49%)       7 (50%)           8 (53%)            4 (40%)        0.85
  Not satisfactorily explained by post-mortem technique, n (%)                          5 (13%)        4 (29%)            1 (7%)            0 (0%)         0.13

Categorized by duration of antiretroviral therapy (ART) at the time of death. Pre-ART deaths occurred in subjects who were HIV-positive and eligible for ART but had not yet received it (CD4 cell count \<200 cells/mm^3^) or those who had received \<7 days of ART. Early ART deaths occured between 7--90 days of ART. Late ART deaths occurred after \>90 days of ART.

All causes of death (immediate and contributing) are included and each subject may have multiple causes of death.

Non-infectious organ dysfunction, ie. pulmonary embolus or end stage renal disease.

At least one cause of death was revealed only through the post-mortem investigations.

10.1371/journal.pone.0047542.t004

###### Immediate and contributing cause(s) of death with supporting clinical, microbiologic and histologic findings.

![](pone.0047542.t004){#pone-0047542-t004-4}

  A. Patients never treated with ART or with \<7 days of ART at time of death                                                                                                                                                                                                                                                                                                                                                                           
  ----------------------------------------------------------------------------- ----- ----- ------ ----- ---- ----------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------ ------------------------------------------------------------------- --------------------------------------------------------------------------------------------
  E03                                                                            39M   30     0     201   10                  dyspnea, infiltrates                                                                          none                                                                                                 PJP (lung)                                                                         PJP                                                                             none
  E04                                                                            29F   175    0      2    14               fever, HSM, ileus, ascites                                     *K. pneumoniae (blood*∧*),* MTB *(lung*∧∼, *spleen*∼, *liver*∼, *BM*∼*)*                                               Nec. gran. inflam (liver capsule%, spleen)                                               *K. pneumoniae* sepsis                                    Dissem. MTB[\*](#nt114){ref-type="table-fn"}, Abdominal infection\#
  E08                                                                            37F   49     0      0    30           vomiting, dyspnea, fever, confusion                                             *C. neoformans* (blood∧, lung∼, spleen∼, CSF∼)                                                                  Cryptococcosis (lung, kidney)                                      Dissem. cryptococcosis[\*](#nt114){ref-type="table-fn"}                                                   none
  E10                                                                            33F   45     0      2    40   cough, LAD, abdominal pain, confusion, pancytopenia     *A. baumannii* (sputum∧, spleen∼), *E. cloacae* (blood∧, lung∼, urine∧), *E. coli* (blood∧, urine∧), MTB (LN&)       Bacterial PNA, Nec. gran. Inflam. (liver, kidney, pancreas, BM, LN%), Pylonephritis                            Polymicrobial sepsis                            Dissem. MTB, Acinetobacter PNA[\*](#nt114){ref-type="table-fn"}, Abdominal infection\#
  E11                                                                            46F   18     0      1    10           HA, meningismus, pulm. infiltrates                                                 MTB (BM&, lung∼&, liver∼&, LN&, spleen∼)                                                     Nec. gran. inflam (BM%, kidney%, liver%, lung%, LN%, spleen%)                                            Dissem. MTB                                                                         None
  E12                                                                            54M   111    0     112   13               fever, dyspnea, hemiparesis                                                               *E. coli* (lung∼)                                                                Aspiration bronchopneumonia, Residual gran. Inflam. (BM, spleen)                                     Aspiration pneumonia                                                               CVA, Dissem. MTB
  E15                                                                            33M   168    0      1    4            fever, meningismus, lymphoctyic CSF                                                                  none                                                                      Non-specific lymphoplasmacytic inflam. (kidney, liver, lung, LN)                                         Meningitis\#                                                                         none
  E21                                                                            29F    6     0     47    30              fever, cough, jaundice, ileus                                                MTB (BM&, CSF∼, liver∼&, lung& LN∼&, spleen∼)                                              CMV pneumonitis, Nec. gran. inflam. (BM, kidney%, liver, lung%, pleura%)                                      Dissem. MTB                                                   CMV pneumonitis[\*](#nt114){ref-type="table-fn"}
  E22                                                                            38M   180    0      0    16      fever, cough, abdo pain, pancytopenia, sepsis                                 *S.enterica* serogroup D (blood∧, spleen∼), MTB (lung&, LN&)                                                Nec. gran. inflam. (BM, liver, lung, pleura, spleen)                           *S. enterica* sepsis[\*](#nt114){ref-type="table-fn"}                                                Dissem. MTB
  E29                                                                            44M    8     0      2    11        hemiparesis, CN deficit, fever, diarrhea                                                  *K. pneumoniae* (lung∼, spleen∼)                                                          Bilateral organizing PNA, Ill-defined gran. inflam. (spleen)                                      *K. pneumoniae* sepsis                                                         Multifocal brain lesions\#
  E30                                                                            36M   66     0      9    30        jaundice, weight loss, diarrhea, LAD, HSM                                     Hepatitis B (blood∧), MTB (blood∧, lung∼, LN∼&, spleen∼)                                 Active Hepatits B, cirrhosis, ATN, Nec. gran. inflam. (BM, lung%, liver, LN%, spleen)                                Dissem. MTB                                                              Hepatiits B with cirrhosis
  E32                                                                            39M          0      0    35            axillary mass, diplopia, dyspnea                                                                    None                                                                 High grade diffuse large B-cell lymphoma (kidney, liver, lung, LN, spleen)                      High grade diffuse large B-cell lymphoma                                                           none
  E35                                                                            40M   70     4      0    10           fever, dyspnea, KS skin and tongue                                                   MTB (blood∧, BM∼&, liver∼&, spleen∼)                                                         Kaposi Sarcoma (skin), Nec. gran. inflam. (liver, spleen%)                            Dissem. MTB[\*](#nt114){ref-type="table-fn"}                                                          KS
  E36                                                                            37M    9     5      7    47           weakness, fever, LAD, pancytopenia                                                                   None                                                                   Hodgkins Lymphoma (BM, liver, spleen), Invasisve aspergillosis (lung)             Invasive pulmonary aspergillosis[\*](#nt114){ref-type="table-fn"}                                       Hodgkins Lymphoma
  **B. Patients treated with 7--90 days of ART at time of death**                                                                                                                                                                                                                                                                                                                                                                                       
  E25                                                                            39F   48     9      0    3                fever, meningismus, seizure                                                   *C. neoformans* (blood∧, CSF ∧∼, spleen∼)                                                           Cryptococcosis (BM, kidney, liver, lung, pancreas)                        Disseminated cryptococcocis[\*](#nt114){ref-type="table-fn"}                                                 none
  E16                                                                            40M   61     12    207   6                  confusion,bedbound, DIC                                                *Enterobacter sp.* (lung∼), *Klebsiella sp.* (lung∼)                                                                Aspiration bronchopneumonia                                                 Enterobacter and klebsiella sepsis                                             Aspriration PNA, Neurologic process\#
  E37                                                                            33M   99     15     0    5                GI bleeding, shock, uremia                                                                   MTB (liver∼)                                                                        Nec. gran. inflam. (liver, lung, spleen), ESRD, ATN                                     Renal failure with uremic bleeding                                 Dissem. MTB (unmasking IRIS)[\*](#nt114){ref-type="table-fn"}
  E38                                                                            32F   17     16     1    5            diarrhea, confusion, renal failure                                            *Acinetobacter sp*. (lung∼), MAC (lung∼, spleen∼)                                                     Gran. inflam. (BM, liver, lung, spleen), Bacterial PNA                           Dissem. MAC (IRIS)[\*](#nt114){ref-type="table-fn"}                                              Acinetobacter PNA
  E05                                                                            31F   77     17     4    15               fever, meningismus, sepsis                                  MTB (blood∧, BM∼, CSF∼&, liver∼, lung∼&, sputum∧), *C. neoformans* ag (CSF∧∼)                                              Nec. gran. inflam.(spleen%, liver%, BM)                                              Dissem. MTB (unmasking IRIS)                                                    Cryptococcal meningitis (IRIS)
  E01                                                                            39F   22     32     0    40              seizures, ICH, vol. overload                                                                   AFB (BM∼)                                                                                     Diffuse alveolar damage, ESRD                                                           Renal failure                               Dissem. mycobacterial infection (unmasking IRIS)[\*](#nt114){ref-type="table-fn"}, ICH
  E18                                                                            18F   61     32     0    17        hemoptysis, renal failure, HSM, hilar LAD                                            MTB (blood∧, BM∼, liver∼&, lung&, spleen∼)                                                    Nec. gran. inflam. (BM, kidneys%, liver, lungs, spleen), ESRD                   Dissem. MTB (unmasking IRIS)[\*](#nt114){ref-type="table-fn"}                                           Renal failure
  E26                                                                            30M   114    32    132   21    fever, confusion, lacunar infarcts, abnormal CSF                                                *Acinetobacter sp.* (lung∼)                                                            Bacterial PNA, Gran. inflam. (BM, kidney, liver, spleen), PJP                                  Dissem. MTB (paradoxical IRIS)                      Acinetobacter PNA[\*](#nt114){ref-type="table-fn"}, PJP[\*](#nt114){ref-type="table-fn"}
  E06                                                                            32F   249    34    45    9                  dyspnea, abdo pain, HSM                                                         *C. dificile* (stool∧), MTB (CSF∼)                                                               KS (lung, skin), Residual gran. inflam. (spleen)                                              Pulmonary KS (IRIS)                                                      Dissem. MTB, C. difficile colitis
  E33                                                                            43M   156    34    156   5                 fever, HA, confusion, PNA                                                             *C. neoformans* (CSF∧∼)                                                       Cryptococcocis (lung), Nec. gran. inflam. (BM, kidney, liver, lung, spleen)            Dissem. Cryptococcosis (IRIS), Dissem. MTB (paradoxical IRIS)                                                none
  E23                                                                            21M   46     37    60    25                  fever, HSM, hilar LAD                                                                     MTB (lung&)                                                                              Nec. gran. inflam. (liver, lung%, spleen)                                            Dissem. MTB (paradoxical IRIS)                                                       Dilated cardiomyopathy
  E28                                                                            28F   353    50    93    30         diarrhea, abdominal distention, ascites                                         *C. dificile* (stool∧), *E. coli* (lung∼, spleen∼)                                                    ATN, Residual gran. inflam. (liver, lung, LN, spleen)                                           *C. dificile* colitis                                                                Dissem. MTB
  E24                                                                            33M   50     51    86    38     night sweats, cough, CN palsies, hydrocephalus                                                      MTB (lung&, CSF∧∼)                                                                       Gran. inflam. (BM, kidney, liver, lung, pleura)                                         Dissem. MTB (paradoxical IRIS)                                                                none
  E20                                                                            34F    6     55     0    3                dyspnea, skin and palate KS                                                    AFB (liver∼), *E. coli* (lung∼, spleen∼)                                                   Bacterial PNA, Gran. inflam. (kidneys, lung), KS (lung, LN, skin)                                          Dissem. KS                               Dissem. MTB[\*](#nt114){ref-type="table-fn"}, E. coli PNA[\*](#nt114){ref-type="table-fn"}
  E13                                                                            57M   154    73     0    21             fever, LAD, skin and palate KS                                                             MTB (lung∼, spleen∼)                                                            Nec. gran. inflam. (kidney, liver, lung, LN, spleen), KS (LN, skin)                Dissem. MTB (unmasking IRIS)[\*](#nt114){ref-type="table-fn"}                                                 KS
  **C. Patients treated with \>90 days of ART at time of death**                                                                                                                                                                                                                                                                                                                                                                                        
  E07                                                                            28M   47     92    184   9                   swollen leg, dyspnea                                                                    MTB (lung&, BM&)                                                                     Pulmonary infarct, Nec. gran. inflam. (liver, spleen)                                             Pulmonary embolus                                                                  Dissem. MTB
  E19                                                                            36F   175   132    27    30        ascites, abdo pain, pleural effusion, LAD        *Clostridium sp.* (lung∼, spleen∼), *Enterobacter sp* (spleen∼), *E. faecium* (blood∧), *E. coli* (lung∼, spleen∼)   Nec. gran. inflam. (LN), KS (LN, spleen), Schistosomiasis (liver, lung), Viral hepatitis                         Polymicrobial sepsis                                                Hepatitis B, KS, MTB adenitis, Schistosomiasis
  E17                                                                            48F   27    148    238   9                 massive cervical LAD, HSM                                                                       None                                                               High grade diffuse large B-cell lymphoma (BM, kidney, liver, lung, LN) spleen)                    High grade diffuse large B-cell lymphoma                                                           none
  E02                                                                            34F         216     0    21          fever, dyspnea, abdominal distention                                                      MTB (lung∧∼&, liver∼&, BM∼)                                                                  Nec. gran. Inflam. (kidney, liver%, spleen%, BM%)                                                  Dissem. MTB                                                                         none
  E31                                                                            32M   760   282     1    7         dypsnea, cardiomegaly, pleural efussions                                                                none                                                            Myocyte hypertrophy, Pulmonary interstitial fibrosis, Biventricular cardiac failure                  Cardiomyopathy with biventricular failure                                                          none
  E27                                                                            42F    2    370     4    8           fever, pancytopenia, meningismus, LAD                                            MTB (blood∧, CSF∼&, liver&, lung∼, LN∼&, pus∧)                                                            Gran. inflam (BM, liver%, lung%, spleen%)                                                      Dissem. MTB                                                                         none
  E14                                                                            56M   14    405    20    50                jaundice, LAD, tender HSM                                                             *C. albicans* (spleen∼)                                                   Candida pyelonephritis, Poorly differentiated malignancy (lung, soft tissue, pleura)            Candida urosepsis[\*](#nt114){ref-type="table-fn"}                            Metastatic malignancy[\*](#nt114){ref-type="table-fn"}\#
  E34                                                                            44M   187   531     0    9    Infected KS lesion, dehydration, confusion, anemia                          *P. mirabilis* (blood∧, lung∼, spleen∼), MTB (lung&, liver&, spleen&)                                        Gran. inflam. (kidney, liver, lung, spleen), KS (lung, skin)                                       *P. mirabilis* sepsis                                          Dissem MTB[\*](#nt114){ref-type="table-fn"}, Dissem. KS
  E09                                                                            29F   28    753     6    7            HTN, vol. overload, confusion, HSM                                                                   none                                                                            ESRD, Nec. gran. Inflam. (BM, liver%, lung, spleen)                                                 Dissem. MTB                                                                    Renal failure
  E39                                                                            36F   43    1113    0    21               cough, HSM, cardiac failure                                                                      none                                                                   Cardiac failure, Polymorphic B-cell NHL (heart, kidney, lung, spleen)                  Polymorphic B-cell NHL[\*](#nt114){ref-type="table-fn"}                                             Cardiac failure

**Symbols**: ∧pre-mortem culture;

post-mortem culture;

detected by PCR;

Ziehl-Neelson stain positive;

unsuspected at time of death;

not satisfactorily explained by post-mortem technique.

**Abbreviations**: **AFB** -- acid fast bacilli; **ag** -- antigen; **ART** -- antiretroviral therapy; **ATN** -- acute tuberular necrosis; **BM** -- bone marrow; **CN** -- cranial nerve; **CSF** -- cerebrospinal fluid; **CMV** -- cytomegalovirus, **CVA** -- cerebrovascular accident; **DIC** -- disseminated intravascular coagulation;**ESRD** -- end stage renal disease; **GI** -- gastrointestingal; **gran.** -- granulmonatous; **HA** -- headache; **HSM** -- hepatosplenomegaly; **HTN** -- hypertension; **ICH** -- intracerebral hemorrhage; **inflam. --** inflammation; **IRIS --** immune reconstitution inflammatory syndrome; **KS --** Kaposi sarcoma; **LAD --** lymphadenopathy; **LN --** lymph node; **MAC --** Mycobacterium avium complex; **MTB --** Mycobacterium tuberculosis; **nec. --** necrotizing; **NHL** -- non-Hodgkins lymhoma; **PCR --** polymerase chain reaction; **PJP --** Pneumocystis iroveci pneumonia; **PNA --** pneumonia; **pulm --** pulmonary; **TBT --** tuberculosis therapy; **vol. --** volume.

Bacterial infections were the second highest overall cause of death (33%, 13/39); with pneumonia and sepsis as the most common manifestations (6 and 7 cases, respectively) and two cases of *C. difficile* colitis. Pneumonia and sepsis were both most often due to gram-negative enterobacteriaceae (7 cases) with 3 cases of noscomial *Acinetobacter* sp. pneumonia. Fungal infections contributed to 21% (8/39) of deaths overall (4 *C. neoformans*, 2 *P. jiroveci*, 1 *C. albicans*, and 1 invasive aspergillosis). The rates of bacterial and fungal causes of death were comparable in the pre-ART group (36% and 21% respectively) and early-ART group (40% and 27%), with a trend towards lower rates in the late-ART group (20% and 10%). Viral infections (other than HIV) contributed to 8% (3/39) of overall deaths (2 Hepatitis B, 1 cytomegalovirus pneumonitis). Schistosomiasis contributed to 1 death. Neoplasm contributed to 21% (3/14) of pre-ART deaths, 20% (3/15) of early-ART deaths and 40% (4/10) of late ART deaths (6 Kaposi's sarcoma, 2 large B-cell lymphomas, 1 Hodgkins lymphoma, 1 metastatic carcinoma of unknown primary). Non-infectious organ failure contributed to 26% (10/39) of deaths (4 renal failure, 3 cardiac failure, 2 neurologic, 1 pulmonary embolus). Causes of death that had not been suspected clinically were revealed by the post-mortem technique in half of the cases (49%, 19/39). Causes of death that the committee determined to be insufficiently explained by the post-mortem technique were identified in 13% (5/39--2 abdominal processes and 3 brain processes, [Table 4](#pone-0047542-t004){ref-type="table"}).

Infectious and neoplastic causes of death were frequently concurrent. Of the 27 subjects with disseminated mycobacterial infection as a cause of death, 62% (17/39) had at least one other infectious or neoplastic cause of death: bacterial infection (6), viral infection (2), fungal infection (2) and neoplasm (2). Three subjects had concurrent neoplasm, bacterial and mycobacterial infections; 1 had concurrent bacterial, fungal and mycobacterial infections, and 1 had concurrent neoplasm, bacterial, viral, parasitic, and mycobacterial infections.

IRIS was implicated in 73% (11/15) of early-ART deaths. IRIS was attributed to mycobacterial infection in 8 cases (6 *M. tuberculosis*, 1 *M. avium*, 1 unspecified mycobacterium), Kaposi sarcoma in 1 case, and both *M. tuberculosis* and *C. neoformans* in 2 cases. The median CD4 cell count for all IRIS cases was 77 cells/mm^3^ (IQR 46--154); and median duration of ART was 32 days (IQR 17--37). Of the 8 TB IRIS cases, 4 were unmasking IRIS and 4 paradoxical IRIS. The unmasking TB IRIS cases were all characterized by necrotizing granulomatous inflammation in multiple organs and positive *M. tuberculosis* tissue cultures ([Table 4](#pone-0047542-t004){ref-type="table"}). The paradoxical TB IRIS cases had a median duration of antituberculosis therapy of 109 days (IQR 80--144). Two paradoxical TB IRIS cases displayed non-necrotizing granulomatous inflammation (ZN negative) and 2 displayed necrotizing granulomatous inflammation (ZN positive). Three of 4 cases had negative TB cultures and the only positive TB culture in this group was from CSF.

Discussion {#s4}
==========

To our knowledge this is the first study from any developing country to use post-mortem investigations to report the causes of mortality for HIV patients on ART. The needle autopsy protocol described here was efficient and resulted in high histologic and mycobacteriologic yield. Tuberculosis was the leading cause of death regardless of ART status and was particularly high in subjects dying in the first 3 months of ART, in whom 87% had disseminated mycobacterial infection as an immediate or contributing cause of death. Multiple concurrent pathologies were common; 62% of subjects dying from mycobacterial infection had at least one additional infectious or neoplastic cause of death. IRIS contributed to 73% of early-ART mortality. Post-mortem investigations revealed clinically unrecognized causes of death in half of the subjects.

The finding that tuberculosis is the leading overall cause of death is consistent with prior autopsy studies of HIV patients from sub-Saharan Africa and India in the pre-ART era. In a 2010 meta-analysis of all autopsy studies of HIV patients from sub-Saharan Africa over the last two decades, tuberculosis was considered a cause of death in 32--45% of 593 autopsied adults. [@pone.0047542-Cox1], [@pone.0047542-Ansari1], [@pone.0047542-Lucas1], [@pone.0047542-Rana1], [@pone.0047542-Murray1] In a series of 236 HIV-positive, ART-naïve patients from Mumbai, tuberculosis was implicated in 63% of deaths. [@pone.0047542-Lanjewar1] Our finding that every case of tuberculosis was disseminated beyond the lungs supports the finding by Martinson *et al.* that in their largely HIV infected, ART-naïve subjects, 97% of those with tuberculosis had evidence of disseminated disease during complete autopsy. [@pone.0047542-Martinson1] Our data on the importance of tuberculosis also support the conclusions of prior studies of cause-specific mortality of HIV patients on ART in low-income settings which used non-pathologic evidence from chart reviews and verbal autopsies. Tuberculosis is consistently among the leading causes of death in these studies, implicated in 16--18% of deaths in studies from Haiti, Senegal and Uganda and in 19--44% of deaths from two South African cohorts.[@pone.0047542-Castelnuovo1], [@pone.0047542-Etard1], [@pone.0047542-Severe1]--[@pone.0047542-Gupta1] The higher number of deaths attributed to tuberculosis in our study is likely explained by the contribution of post-mortem investigations which revealed that a third of microbiologically and/or histologically-proven tuberculosis infections were clinically unsuspected at the time of death.

Our finding that IRIS contributed to over 70% of early-ART deaths highlights the importance and deadly potential of severe IRIS; in cohort studies based at ART clinics the condition has been described as usually self-limited and infrequently fatal. [@pone.0047542-Lawn2], [@pone.0047542-Murdoch1] In cohort studies from Uganda and South Africa that have determined cause of death through chart-review and verbal autopsy, IRIS has been implicated in 7% of early-ART deaths and 17% of all ART-deaths respectively. [@pone.0047542-Castelnuovo1], [@pone.0047542-MacPherson1] Fatal IRIS has been reported, especially in central nervous system infections.[@pone.0047542-Lawn3]--[@pone.0047542-Makadzange1] Although our study setting at a tertiary referral hospital may have influenced our findings, our high rate is supported by detailed clinicopathological data. The fatal cases described here challenge certain characteristics that have been used to define IRIS. In the consensus definition, the presence of another infection excludes IRIS [@pone.0047542-Meintjes1]; however case E26 in this study demonstrates convincing evidence of paradoxical central nervous system TB IRIS with a simultaneous nosocomial bacterial pneumonia. In case E33, exuberant necrotizing granulomatous inflammation of multiple organs convinced the clinico-pathologic committee to diagnose concomitant paradoxical TB IRIS and unmasking cryptococcal IRIS ([Figure 1](#pone-0047542-g001){ref-type="fig"}).

![Simultaneous *C. neoformans* pneumonia and paradoxical *M. tuberculosis* Immune Reconstitution Inflammatory Syndrome (IRIS).\
At the time of death, this patient (E33) had been on anti-tuberculosis therapy for pulmonary tuberculosis for 5 months (with good response to treatment) and antiretroviral therapy for 1 month. Histologic sections demonstrate (a) suppurative consolidation of the lungs with (b) cryptococcal organisms apparent on Grocott's Methanamine Silver (GMS) stain. Kidney (c) and spleen (d) demonstrate well formed necrotizing granulomatous inflammation, with negative Ziehl-Neelsen and GMS stains for organisms; these were thought to represent an exuberant inflammatory response due to paradoxical TB IRIS.](pone.0047542.g001){#pone-0047542-g001}

This study does have a number of limitations. Small sample-size limited the ability of this study to find significant differences between pre-ART, early-ART and late-ART mortality and to pick-up low frequency causes of death. The pathology reported here is a minimum estimate as the needle autopsy was limited to sampled organs and likely missed important pathology in non-sampled organs (particularly in the abdomen/pelvis and cranium); similarly, areas of focal pathology within biopsied organs may have been missed. A study comparing results of needle and conventional autopsies found a concordance on primary cause of death in 67% of cases. [@pone.0047542-Huston1] The predominance of gram-negative organisms in pre- and post-mortem cultures may be due to the translocation of enteric organisms across HIV-damaged gut mucosa and nosocomial pneumonias, but the striking lack of gram-positive cultures is most likely the result of pre-mortem broad-spectrum antibiotics and may have caused us to underestimate the contribution of pathogens like *S. aureus* and *S. pneumonia* to bacterial causes of death. Measuring HIV viral load at the time of death would have been helpful in determining adherence to and effectiveness of ART. This study may have overestimated the impact of IRIS due to miscategorization of overwhelming infections as unmasking IRIS; use of a prospective study design with serial measurements of CD4 cell count and HIV viral load might have more accurately made this distinction. We did not do mycobacterial drug-susceptibility testing which would also have helped clarify whether deteriorations after ART were due to IRIS or drug-resistant disease. [@pone.0047542-Cohen1], [@pone.0047542-Meintjes2].The setting of our study in an urban tertiary referral hospital with access to advanced diagnostic procedures and intensive care facilities may limit the application of our findings to other settings.

The standardized needle autopsy described here was minimally mutilating, was efficient to perform, did not delay burial and had a very high pathological yield. While there is still a need for complete autopsies, in situations that preclude them a version of this needle autopsy protocol, perhaps modified to include brain and abdomen/pelvis sampling, has the potential to provide crucial post-mortem data.

Our findings demonstrate that tuberculosis is the major killer of HIV patients in sub-Saharan Africa, that it is frequently unrecognized and often accompanied by concurrent infections or neoplasms. Because simultaneous complex pathologies contribute to mortality, additional diagnoses should be sought for patients not clinically improving despite receiving treatment for known diagnoses. Additional study of the pathogenesis of and therapeutics for severe IRIS is needed. The development of a comprehensive response to the diagnosis and prevention of tuberculosis prior to and throughout the course of antiretroviral therapy is likely to have an enormous life-saving potential.
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